The impact of the M184V substitution on drug resistance and viral fitness

References

• Lorenzi E, Opravil M, Hirschel B, et al Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 13, F17—F21 (1999).
   PubMedGoogle Scholar
• Quiros-Roldan E, Signorini S, Castelli F, et al. Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. J. Clin. Lab. Anal. 15, 43–46 (2001).
   PubMed Web of Science ®Google Scholar
• Rousseau MN, Vergne L, Montes B, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 26, 36–43 (2001).
   PubMed Web of Science ®Google Scholar
• Winters MA, Baxter JD, Mayers DL, etal. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antiviral Ther. 5, 57–63 (2000).
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288, 222–235 (2002).
   PubMed Web of Science ®Google Scholar
• Balotta C, Berlusconi A, Pan A, etal. Prevalence of transmitted nucleoside analog-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antiviral Ther 5, 7–14 (2000).
   Google Scholar
• de Jong MD, Schuurman R, Lange JM, Boucher CA. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antiviral Ther. 1, 33–41 (1996).
   PubMedGoogle Scholar
• Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am. J. Med. 102, 70–75 (1997).
   PubMedGoogle Scholar
• Condra J. Virologic and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist. Updates 1, 292–299 (1998).
   Google Scholar
• Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv. Exp. Med. Biol. 458, 175–182 (1999).
   PubMed Web of Science ®Google Scholar
• Molla A, Korneyeva M, Gao Q, etal. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2,760–766 (1996).
   PubMed Web of Science ®Google Scholar
• Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus Type 1-infected individuals: the relative roles of drift and selection. J Virol. 74,6262–6268 (2000).
   PubMed Web of Science ®Google Scholar
• Gotte M, Wainberg MA. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist. Update 3,30–38 (2000).
   PubMed Web of Science ®Google Scholar
• Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. Acquired Immune Defic. Synth: 26 (Suppl. 1), S10—S24 (2001).
   Google Scholar
• Bacheler L, Jeffrey S, Hanna G, etal. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 75, 4999–5008 (2001).
   PubMed Web of Science ®Google Scholar
• Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. Acquired Immune Defic. Synth: 26 (Suppl. 1), S25—S33 (2001).
   Google Scholar
• Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2 '-deoxy-3 '-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus Type 1 reverse transcriptase. Antirnicrob. Agents Chernother. 37,2231–2234 (1993).
   PubMed Web of Science ®Google Scholar
• Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus Type 1 resistance to 2 ',3'-dideoxyinosine and 2 ',3 dideoxycytidine confers high-level resistance to the (-) enantiomer of 2 ',3 '-dideoxy-3'-thiacytidine. Antirnicrob. Agents Chernother 37,1390–1392 (1993).
   PubMed Web of Science ®Google Scholar
• Hertogs K, Bloor S, De Vroey V, etal. A novel human immunodeficiency virus Type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob. Agents Chernother. 44, 568–573 (2000).
   PubMed Web of Science ®Google Scholar
• Quan Y, Gu Z, Li X, etal. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2 '-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus Type 1.1 Virol. 70,5642–5645 (1996).
   Web of Science ®Google Scholar
• Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus Type 1 resistant to 3 '-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl Acad. Sci. USA 90, 5653–5656 (1993).
   PubMed Web of Science ®Google Scholar
• Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. j Virol. 75,4832–4842 (2001).
   Web of Science ®Google Scholar
• Gotte M, Anion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus Type 1 impairs rescue of chain-terminated DNA synthesis. J Virol. 74, 3579–3585 (2000).
   PubMed Web of Science ®Google Scholar
• Isel C, Ehresmann C, Walter P, Ehresmann B, Marquet R. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wildtype HIV-1 reverse transcriptase. Biol. Chem. 276,48725–48732 (2001).
   Web of Science ®Google Scholar
• Masquelier B, Descamps D, Carriere I, etal. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study. Antiviral Ther. 4,69–77 (1999).
   PubMed Web of Science ®Google Scholar
• Meyer PR, Matsuura SE, Mian AM, Therefore, AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell. 4, 35–43 (1999).
   PubMed Web of Science ®Google Scholar
• Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The M184V mutation reduces the selective excision of zidovudine 5 monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus Type 1.1 Vim]. 76,3248–3256 (2002).
   Google Scholar
• Quan Y, Gu Z, Li X, etal. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. j Mol. Biol. 277,237–247 (1998).
   Web of Science ®Google Scholar
• Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. 4,87–94 (1999).
   PubMed Web of Science ®Google Scholar
• Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus Type 1 containing the M184V mutation. Antirnicrob. Agents Chernother. 47,747–754 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science242, 1171–1173 (1988).
   Google Scholar
• Menendez-Arias L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucleic Acid Res. Mol. Biol. 71,91–147 (2002).
   PubMedGoogle Scholar
• Jonckheere H, Witvrouw M, De Clercq E, Anne J. Lamivudine resistance of HIV Type 1 does not delay development of resistance to nonnucleoside HIV Type 1-specific reverse transcriptase inhibitors as compared with wildtype HIV Type 1. AIDS Res. Hum. Retroviruses. 14,249–253 (1998).
   PubMed Web of Science ®Google Scholar
• Picard V, Angelini E, Maillard A, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus Type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect. Dis. 184,781–784 (2001).
   PubMed Web of Science ®Google Scholar
• Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus Type 1. Antirnicrob. Agents Chernother. 39,1624–1628 (1995).
   PubMed Web of Science ®Google Scholar
• Anion D, Kaushik N, McCormick S, Borkow G and Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3 azido-3 '-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochernistry37, 15908–15917 (1998).
   Google Scholar
• Back NK, Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus Type 1 reverse transcriptase. Antirnicrob. Agents Chernother. 41,2484–2491 (1997).
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus Type 1 isolates in vitro. J Virol. 72,3773–3778 (1998).
   PubMed Web of Science ®Google Scholar
• Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus Type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. j Virol. 73,8448–8456 (1999).
   Web of Science ®Google Scholar
• Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multi-drug resistant human immunodeficiency virus Type 1 acquired in primary infection. J Viral. 76,1753–1761 (2002).
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Matthews TB, Higgins J, etal. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Viral. 76,6083–6092 (2002).
   PubMed Web of Science ®Google Scholar
• Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wildtype human immunodeficiency virus Type 1. AIDS Res. Hum. Retroviruses 14,735–740 (1998).
   PubMed Web of Science ®Google Scholar
• Picchio GR, Valdez H, Sabbe R, etal. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquire Immune Belk. Syndr. 25,289–295 (2000).
   PubMed Web of Science ®Google Scholar
• Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl. J Med. 333, 1662–1669 (1995).
   PubMed Web of Science ®Google Scholar
• Maguire M, Gartland M, Moore S, etal. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS14, 1195–1201 (2000).
   Google Scholar